Late Lessons, Jensen Huang and AI
Markdown version

LL2-08 digest — Ch8 Vinyl chloride: a saga of secrecy#

EEA 2013, report pp. 179–202 (PDF 181–204). The chapter is by Soffritti (Scientific Director, Ramazzini Institute / Cesare Maltoni Cancer Research Center), Sass (NRDC), Castleman (public-interest consultant) and Gee (EEA editor). Panel 8.1 is by Charlie Clutterbuck (UK activist-scientist memoir). Panel 8.2 is by James Huff (NIEHS; defends animal bioassays). There is no industry or regulator panel.

Core story#

The US workplace limit for vinyl chloride (VC) was 500 ppm from 1954. It rested on a single 1930s guinea-pig study (p. 193, fn 10) and was set through a voluntary body whose limits reflected “what the industry felt was achievable” (p. 182).

Early warnings. From 1959 companies had credible internal warnings. Dow’s toxicologist warned of “appreciable injury” at 500 ppm, and Union Carbide’s consultant found VC “more toxic than has been believed” (pp. 182–183). In 1961 Dow published liver effects at 100–200 ppm, and company toxicologists recommended ≤50 ppm (pp. 180, 182).

Bone disease, kept quiet (1963–1971). A Romanian clinical study had described VC-linked acroosteolysis (AOL), a rare and painful bone disease, in 1963 (p. 183). Companies shared their own AOL findings among themselves. At a private June 1966 meeting they learned that 1% of PVC workers and 6% of vat cleaners had it. They kept this from workers and regulators (“use discretion”, “an adequate story”, p. 183). The record was edited: - VC causation was cut from a 1967 paper (p. 183). - An MCA committee voted 7–3 to refuse an MCA-funded report as written. It then accepted the report unanimously once it stated that the “etiologic agent of the disease is unknown” (p. 184). - Goodrich refused further research so industry could “act as if the cause was ‘unknown’” (p. 184). - Fifty member companies objected to a proposed 50 ppm limit, and the ACGIH put it off (1966, p. 184).

Cancer, withheld from regulators (1972–1973). A Solvay-commissioned study found cancers at 30,000 ppm and was reported publicly in 1970. Maltoni’s programme, mainly publicly funded and co-funded by European producers, found liver (including angiosarcoma) and kidney cancer at 250 ppm. This was revealed to US and European firms in November 1972. US and European firms signed a secrecy agreement (Fig. 8.1) and did not disclose the 250 ppm result to NIOSH in July 1973, although it had been presented at a scientific symposium in April (pp. 180, 184–186).

Disclosure and rapid action (1974–75). In January 1974 Goodrich announced it was investigating three workers’ deaths from liver angiosarcoma at its Louisville plant. Company physician John Creech had identified four, all in the polymerisation section. He eventually found seven (1964–74), all among reactor “pot cleaners” (p. 186). Action was then fast. OSHA cut the limit to 50 ppm and then to 1 ppm within months. A federal appeals court upheld the standard in January 1975. It found that “strong warning signals … of long before” had been ignored and that “the factual finger” pointed to a low limit even though the science was “on the frontiers of scientific knowledge” (Box 8.1, p. 187). The box’s phrase “delay, feigned ignorance and irresponsibility” is its own characterisation, not a quotation from the ruling. Steam-stripping cut residual monomer by 99%. An unsourced “analysis in 2000” put compliance at USD 278 million, against industry forecasts of up to USD 90 billion and 2 million jobs, and the industry kept growing (pp. 187, 192).

Continuing disputes. Epidemiology on other cancers (brain, lung, lymphohaematopoietic) remained contested. The chapter documents an industry-funded study that excluded long-exposed workers, the healthy-worker effect, and a brain-cancer finding retracted “at the request of the chemical industry” (pp. 187–188). IARC 2008 confirms only angiosarcoma and hepatocellular carcinoma as established (Box 8.2, p. 191).

Authors’ lessons (pp. 191–193)#

  1. Action came from a publicised signature cancer, strong animal evidence, new agencies and activism.
  2. A simple fix “had been available all along”; regulation spurred innovation.
  3. Predicted economic collapse did not happen.
  4. Corporate conscience “rarely if ever” suffices; regulation, liability and informed markets do.
  5. Bioassays predicted even target organs.
  6. Limits should keep falling.
  7. Epidemiology “certainly underestimated” the risk; relying on it alone means “count[ing] the bodies” (pp. 192–193).
  8. Carcinogenesis studies should inform societal decisions.

Further recommendations: - Reverse the burden of proof so “risk makers, not risk takers” show safety (p. 187). - Pair no-fault compensation with ways to extract corporate information, since document discovery in compensation cases can reveal “until then secret” corporate conduct (p. 179).

Main mechanisms#

Transferable insights (selection; full list with ratings in notes)#

Main caveats#